What’s the current market cap for Establishment Labs stock?

Establishment Labs (ESTA) has a market cap of $2.1B as of May 25, 2026.

What is the P/E ratio for Establishment Labs stock?

The price to earnings (P/E) ratio for Establishment Labs (ESTA) stock is 0 as of May 25, 2026.

Does Establishment Labs stock pay dividends?

No, Establishment Labs (ESTA) stock does not pay dividends to its shareholders as of May 25, 2026.

When is the next Establishment Labs dividend payment date?

Establishment Labs (ESTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Establishment Labs?

Establishment Labs (ESTA) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Establishment Labs stock | $ESTA Share Price

13:30

15:10

16:45

18:25

20:00

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Ticker

$ESTA

Sector

Health

Primary listing

NASDAQ

Employees

1,004

Headquarters

Austin, United States

Website

www.establishmentlabs.com

ESTA Metrics

BasicAdvanced

$2.1bn

-$1.47

1.12

What the Analysts think about ESTA

Analyst ratings (Buy, Hold, Sell) for Establishment Labs stock.

Bulls say / Bears say

Establishment Labs reported Q4 EPS of –$0.09, beating estimates by $0.13, and revenue of $64.6 million, which surpassed the $63.75 million consensus. FY2026 revenue guidance of $264–266 million is also above analysts’ expectations of $263 million (Reuters).

The company has applied for FDA approval to use its Motiva implants in both primary and revision breast reconstruction, extending its reach beyond augmentation. Over 60,000 implants have been sold in the U.S. since initial FDA approval, contributing to revenue growth of 24.76% over the past year (Reuters).

Top analysts including Mizuho, Needham, and BTIG have raised price targets to $85, $84, and $81 respectively, based on strong Q3 2025 performance and rapid U.S. market adoption, showing increased confidence in the company’s growth outlook (Reuters).

Establishment Labs remains unprofitable, posting a Q4 EPS of –$0.09 and a negative earnings yield of –4%, which highlights continued difficulties in generating profits (Reuters).

The stock has surged more than 109% over the past year and is now trading above fair value, raising concerns about overvaluation and increasing the risk of a pullback if the market corrects (Reuters; Reuters).

Revenue is still highly concentrated in Motiva silicone gel–filled implants and Motiva Flora tissue expanders, pointing to limited product diversification and exposing the business to greater revenue volatility (Trefis).

Data summarised monthly by Lightyear AI. Last updated on 27 Apr 2026.

ESTA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ESTA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ESTA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Establishment Labs remains unprofitable, posting a Q4 EPS of –$0.09 and a negative earnings yield of –4%, which highlights continued difficulties in generating profits (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 27 Apr 2026.